Structure and Development of Single Domain Antibodies As Modules for Therapeutics and Diagnostics

Overview

Journal Exp Biol Med (Maywood)

Specialty Biology

Date 2019 Oct 10

PMID 31594404

Citations 23

Authors

Robert J Hoey

Hyeyoung Eom

James R Horn

Affiliations

Soon will be listed here.

Citing Articles

The potential role of nanobodies in asthma therapy.

Khalid Salah Al-Sheakly B, Saheb Sharif-Askari F, Sharif-Askari N, Hundt J, Halwani R Front Pharmacol. 2025; 15:1510806.

PMID: 39902079 PMC: 11788342. DOI: 10.3389/fphar.2024.1510806.

The process using a synthetic library that generates multiple diverse human single domain antibodies.

Tornetta M, Whitaker B, Cantwell O, Pisors E, Han L, MacWilliams M Antib Ther. 2024; 7(4):283-294.

PMID: 39381136 PMC: 11456836. DOI: 10.1093/abt/tbae020.

Single-domain antibodies as therapeutics for solid tumor treatment.

Wang M, Ying T, Wu Y Acta Pharm Sin B. 2024; 14(7):2854-2868.

PMID: 39027249 PMC: 11252471. DOI: 10.1016/j.apsb.2024.03.016.

Generation and characterization of nanobodies targeting GPCR.

Zhang S, Fan Z, Liu J Biophys Rep. 2024; 10(1):22-30.

PMID: 38737476 PMC: 11079602. DOI: 10.52601/bpr.2023.230026.

Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2.

Longsompurana P, Rungrotmongkol T, Plongthongkum N, Wangkanont K, Wolschann P, Poo-Arporn R PLoS One. 2023; 18(10):e0293263.

PMID: 37874836 PMC: 10597523. DOI: 10.1371/journal.pone.0293263.

References

Tabasinezhad M, Talebkhan Y, Wenzel W, Rahimi H, Omidinia E, Mahboudi F . Trends in therapeutic antibody affinity maturation: From in-vitro towards next-generation sequencing approaches. Immunol Lett. 2019; 212:106-113. DOI: 10.1016/j.imlet.2019.06.009. View

Crowe J, Roberts K, Carlton T, Maggiore L, Cubitt M, Clare S . Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease. Sci Rep. 2018; 8(1):4941. PMC: 5862986. DOI: 10.1038/s41598-018-23277-7. View

Wu Y, Jiang S, Ying T . Single-Domain Antibodies As Therapeutics against Human Viral Diseases. Front Immunol. 2018; 8:1802. PMC: 5733491. DOI: 10.3389/fimmu.2017.01802. View

Che T, Majumdar S, Zaidi S, Ondachi P, McCorvy J, Wang S . Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor. Cell. 2018; 172(1-2):55-67.e15. PMC: 5802374. DOI: 10.1016/j.cell.2017.12.011. View

Conrath K, Lauwereys M, Galleni M, Matagne A, Frere J, Kinne J . Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother. 2001; 45(10):2807-12. PMC: 90735. DOI: 10.1128/AAC.45.10.2807-2812.2001. View

Fanning S, Murtaugh M, Horn J . A combinatorial approach to engineering a dual-specific metal switch antibody. Biochemistry. 2011; 50(23):5093-5. DOI: 10.1021/bi2003845. View

Franco E, Sonneson G, DeLegge T, Hofstetter H, Horn J, Hofstetter O . Production and characterization of a genetically engineered anti-caffeine camelid antibody and its use in immunoaffinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 878(2):177-86. DOI: 10.1016/j.jchromb.2009.06.017. View

Goldman E, Liu J, Zabetakis D, Anderson G . Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview. Front Immunol. 2017; 8:865. PMC: 5524736. DOI: 10.3389/fimmu.2017.00865. View

van Witteloostuijn S, Pedersen S, Jensen K . Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation. ChemMedChem. 2016; 11(22):2474-2495. DOI: 10.1002/cmdc.201600374. View

10.

Saerens D, Pellis M, Loris R, Pardon E, Dumoulin M, Matagne A . Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol. 2005; 352(3):597-607. DOI: 10.1016/j.jmb.2005.07.038. View

11.

De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J . Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A. 2006; 103(12):4586-91. PMC: 1450215. DOI: 10.1073/pnas.0505379103. View

12.

Wagner H, Wehrle S, Weiss E, Cavallari M, Weber W . A Two-Step Approach for the Design and Generation of Nanobodies. Int J Mol Sci. 2018; 19(11). PMC: 6274671. DOI: 10.3390/ijms19113444. View

13.

Moutel S, Bery N, Bernard V, Keller L, Lemesre E, de Marco A . NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife. 2016; 5. PMC: 4985285. DOI: 10.7554/eLife.16228. View

14.

HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

15.

King M, Huh I, Shenai A, Brooks T, Brooks C . Structural basis of VH-mediated neutralization of the food-borne pathogen . J Biol Chem. 2018; 293(35):13626-13635. PMC: 6120195. DOI: 10.1074/jbc.RA118.003888. View

16.

van der Linden R, Frenken L, de Geus B, Harmsen M, Ruuls R, Stok W . Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta. 1999; 1431(1):37-46. DOI: 10.1016/s0167-4838(99)00030-8. View

17.

De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K . Nanobody Based Dual Specific CARs. Int J Mol Sci. 2018; 19(2). PMC: 5855625. DOI: 10.3390/ijms19020403. View

18.

De Vlieger D, Ballegeer M, Rossey I, Schepens B, Saelens X . Single-Domain Antibodies and Their Formatting to Combat Viral Infections. Antibodies (Basel). 2019; 8(1). PMC: 6640686. DOI: 10.3390/antib8010001. View

19.

Muyldermans S . Single domain camel antibodies: current status. J Biotechnol. 2001; 74(4):277-302. DOI: 10.1016/s1389-0352(01)00021-6. View

20.

Ding L, Tian C, Feng S, Fida G, Zhang C, Ma Y . Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy. Theranostics. 2015; 5(4):378-98. PMC: 4329502. DOI: 10.7150/thno.10084. View